Small dense LDL-2 (sdLDL-2) is the second smallest-density LDL subfraction measured in comprehensive lipid panel testing. Like all small dense LDL particles, sdLDL-2 is more atherogenic than larger LDL-1 and LDL-2 particles — it penetrates the arterial intima more readily, is more prone to oxidation, and contributes more significantly to plaque development.
Elevated sdLDL-2 alongside other small dense LDL subfractions reflects a Pattern B LDL phenotype, characteristic of individuals with insulin resistance, type 2 diabetes, or metabolic syndrome. Identifying this pattern allows for targeted interventions — low-carbohydrate dietary approaches and triglyceride-lowering medications tend to shift the LDL particle distribution back toward larger, less harmful particles.
FAQs
Are sdLDL-2 particles dangerous?
Yes. sdLDL-2 particles are smaller and denser than large LDL, making them more prone to oxidation and arterial wall penetration, contributing to plaque formation.
Is sdLDL testing routine?
No. Small dense LDL subfraction analysis is specialised testing, most useful in people with metabolic syndrome or borderline standard lipids.
What shifts LDL toward small dense particles?
High triglycerides from refined carbohydrate excess and insulin resistance drive CETP-mediated exchanges that remodel large LDL into smaller, denser particles.
How do statins affect sdLDL?
Statins reduce total particle number including sdLDL, but do not dramatically shift particle size. Fibrates and carbohydrate restriction more specifically reduce small dense LDL proportions.
